153 related articles for article (PubMed ID: 38000655)
1. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition.
Bedard GT; Gilaj N; Peregrina K; Brew I; Tosti E; Shaffer K; Tyler PC; Edelmann W; Augenlicht LH; Schramm VL
J Biol Chem; 2024 Jan; 300(1):105492. PubMed ID: 38000655
[TBL] [Abstract][Full Text] [Related]
2. Transition state analogue of MTAP extends lifespan of APC
Firestone RS; Feng M; Basu I; Peregrina K; Augenlicht LH; Schramm VL
Sci Rep; 2021 Apr; 11(1):8844. PubMed ID: 33893330
[TBL] [Abstract][Full Text] [Related]
3. MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
Kalev P; Hyer ML; Gross S; Konteatis Z; Chen CC; Fletcher M; Lein M; Aguado-Fraile E; Frank V; Barnett A; Mandley E; Goldford J; Chen Y; Sellers K; Hayes S; Lizotte K; Quang P; Tuncay Y; Clasquin M; Peters R; Weier J; Simone E; Murtie J; Liu W; Nagaraja R; Dang L; Sui Z; Biller SA; Travins J; Marks KM; Marjon K
Cancer Cell; 2021 Feb; 39(2):209-224.e11. PubMed ID: 33450196
[TBL] [Abstract][Full Text] [Related]
4. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
Marjon K; Cameron MJ; Quang P; Clasquin MF; Mandley E; Kunii K; McVay M; Choe S; Kernytsky A; Gross S; Konteatis Z; Murtie J; Blake ML; Travins J; Dorsch M; Biller SA; Marks KM
Cell Rep; 2016 Apr; 15(3):574-587. PubMed ID: 27068473
[TBL] [Abstract][Full Text] [Related]
5. Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous
Konteatis Z; Travins J; Gross S; Marjon K; Barnett A; Mandley E; Nicolay B; Nagaraja R; Chen Y; Sun Y; Liu Z; Yu J; Ye Z; Jiang F; Wei W; Fang C; Gao Y; Kalev P; Hyer ML; DeLaBarre B; Jin L; Padyana AK; Dang L; Murtie J; Biller SA; Sui Z; Marks KM
J Med Chem; 2021 Apr; 64(8):4430-4449. PubMed ID: 33829783
[TBL] [Abstract][Full Text] [Related]
6. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
[TBL] [Abstract][Full Text] [Related]
7. Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5'-methylthioadenosine phosphorylase.
Basu I; Locker J; Cassera MB; Belbin TJ; Merino EF; Dong X; Hemeon I; Evans GB; Guha C; Schramm VL
J Biol Chem; 2011 Feb; 286(6):4902-11. PubMed ID: 21135097
[TBL] [Abstract][Full Text] [Related]
8. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine.
Barekatain Y; Ackroyd JJ; Yan VC; Khadka S; Wang L; Chen KC; Poral AH; Tran T; Georgiou DK; Arthur K; Lin YH; Satani N; Ballato ES; Behr EI; deCarvalho AC; Verhaak RGW; de Groot J; Huse JT; Asara JM; Kalluri R; Muller FL
Nat Commun; 2021 Jul; 12(1):4228. PubMed ID: 34244484
[TBL] [Abstract][Full Text] [Related]
9. The potential and challenges of targeting
Bray C; Balcells C; McNeish IA; Keun HC
Front Oncol; 2023; 13():1264785. PubMed ID: 37795443
[TBL] [Abstract][Full Text] [Related]
10. A patent review of MAT2a inhibitors (2018-2021).
Atkinson SJ; Evans L; Scott JS
Expert Opin Ther Pat; 2022 Oct; 32(10):1043-1053. PubMed ID: 36043503
[TBL] [Abstract][Full Text] [Related]
11. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
Kryukov GV; Wilson FH; Ruth JR; Paulk J; Tsherniak A; Marlow SE; Vazquez F; Weir BA; Fitzgerald ME; Tanaka M; Bielski CM; Scott JM; Dennis C; Cowley GS; Boehm JS; Root DE; Golub TR; Clish CB; Bradner JE; Hahn WC; Garraway LA
Science; 2016 Mar; 351(6278):1214-8. PubMed ID: 26912360
[TBL] [Abstract][Full Text] [Related]
12. The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity.
Xuan YF; Lu S; Ou YJ; Bao XB; Huan XJ; Song SS; Miao ZH; Wang YQ
Biochem Biophys Res Commun; 2024 Jul; 716():150011. PubMed ID: 38704890
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
14. Targeting the methionine-methionine adenosyl transferase 2A- S -adenosyl methionine axis for cancer therapy.
Guo J; Yang Y; Buettner R; Rosen ST
Curr Opin Oncol; 2022 Sep; 34(5):546-551. PubMed ID: 35788128
[TBL] [Abstract][Full Text] [Related]
15. Phosphoinositide and redox dysregulation by the anticancer methylthioadenosine phosphorylase transition state inhibitor.
Salita T; Rustam YH; Hofferek V; Jackson M; Tollestrup I; Sheridan JP; Schramm VL; Evans GB; Reid GE; Munkacsi AB
Biochim Biophys Acta Mol Cell Biol Lipids; 2023 Sep; 1868(9):159346. PubMed ID: 37301365
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Fedoriw A; Rajapurkar SR; O'Brien S; Gerhart SV; Mitchell LH; Adams ND; Rioux N; Lingaraj T; Ribich SA; Pappalardi MB; Shah N; Laraio J; Liu Y; Butticello M; Carpenter CL; Creasy C; Korenchuk S; McCabe MT; McHugh CF; Nagarajan R; Wagner C; Zappacosta F; Annan R; Concha NO; Thomas RA; Hart TK; Smith JJ; Copeland RA; Moyer MP; Campbell J; Stickland K; Mills J; Jacques-O'Hagan S; Allain C; Johnston D; Raimondi A; Porter Scott M; Waters N; Swinger K; Boriack-Sjodin A; Riera T; Shapiro G; Chesworth R; Prinjha RK; Kruger RG; Barbash O; Mohammad HP
Cancer Cell; 2019 Jul; 36(1):100-114.e25. PubMed ID: 31257072
[TBL] [Abstract][Full Text] [Related]
17. Fragment-Based Design of a Potent MAT2a Inhibitor and
De Fusco C; Schimpl M; Börjesson U; Cheung T; Collie I; Evans L; Narasimhan P; Stubbs C; Vazquez-Chantada M; Wagner DJ; Grondine M; Sanders MG; Tentarelli S; Underwood E; Argyrou A; Smith JM; Lynch JT; Chiarparin E; Robb G; Bagal SK; Scott JS
J Med Chem; 2021 May; 64(10):6814-6826. PubMed ID: 33900758
[TBL] [Abstract][Full Text] [Related]
18. Selective PRMT5 Inhibitors Suppress Human CD8
Strobl CD; Schaffer S; Haug T; Völkl S; Peter K; Singer K; Böttcher M; Mougiakakos D; Mackensen A; Aigner M
Mol Cancer Ther; 2020 Feb; 19(2):409-419. PubMed ID: 31712395
[TBL] [Abstract][Full Text] [Related]
19. Extracellular 5'-methylthioadenosine inhibits intracellular symmetric dimethylarginine protein methylation of FUSE-binding proteins.
Tang B; Lee HO; Gupta S; Wang L; Kurimchak AM; Duncan JS; Kruger WD
J Biol Chem; 2022 Sep; 298(9):102367. PubMed ID: 35963436
[TBL] [Abstract][Full Text] [Related]
20. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of
Smith CR; Aranda R; Bobinski TP; Briere DM; Burns AC; Christensen JG; Clarine J; Engstrom LD; Gunn RJ; Ivetac A; Jean-Baptiste R; Ketcham JM; Kobayashi M; Kuehler J; Kulyk S; Lawson JD; Moya K; Olson P; Rahbaek L; Thomas NC; Wang X; Waters LM; Marx MA
J Med Chem; 2022 Feb; 65(3):1749-1766. PubMed ID: 35041419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
